Nasal drug delivery systems market

Nasal Drug Delivery Systems Market, by Dosage Form (Nasal Spray, Nasal Drops, Nasal Gels, Nasal Powders, and Others), by Container Type (Non-pressurized Containers and Pressurized Containers), by System Type (Multi Dose, Bi Dose, and Unit Dose), by Therapeutics Application (Allergic and Non-allergic Rhinitis, Nasal Congestion, Vaccination, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Nov 2022
CMI1944
156 Pages
Excel & Pdf
Medical Devices

Summary

Nasal drug delivery system is an alternative to invasive administrations and provides direct access to systemic circulation. Intranasal drug delivery is common and most preferred route of administration in treatment of allergic and non-allergic rhinitis, pain, acute treatment of migraine, and nasal congestion associated with sinusitis, common cold or rhinitis. Nasal drug delivery systems are mostly used in case wherein rapid onset of action is required, or to reach the site where other routes of administration display ineffective results. Nasal drug delivery is also preferred route for needle-free vaccination and systemic drug delivery. Liquid nasal preparations can be administered through inhalers, droppers, spray pumps, nebulizers or atomizers.

Global nasal drug delivery systems market is estimated to be valued at US$ 60.3 million in 2022 and is expected to exhibit a CAGR of 6.3% during the forecast period (2022-2030).

Figure 1. Global Nasal Drug Delivery Systems Market Share (%), by Dosage Form, 2022

Increasing product approvals by regulatory authorities is expected to drive growth of the global nasal drug delivery systems market.

Increasing product approvals by regulatory authorities is expected to drive growth of the global nasal drug delivery systems market. For instance, on March 18, 2019, Aptar Pharma, a drug delivery systems provider, had announced that the company’s product Bidose nasal spray device had received approval from the U.S. Food and Drug administration (FDA) for a breakthrough therapy in the field of depression.

Nasal Drug Delivery Systems Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 60.3 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	6.3%	2030 Value Projection:	US$ 98.4 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Dosage Form: Nasal Spray, Nasal Drops, Nasal Gels, Nasal Powders, Others By Container Type: Non-pressurized Containers, Pressurized Containers By System Type: Multi Dose, Bi Dose, Unit Dose By Therapeutics Application: Allergic and Non-allergic Rhinitis, Nasal Congestion, Vaccination, Others By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Baxter International, Inc., Valeant Pharmaceuticals International, Inc., Becton, Dickinson and Company, and Novartis AG
Growth Drivers:	Increasing product approvals by regulatory authorities Increasing product launches by market players
Restraints & Challenges:	Limitations associated with nasal drug delivery systems

Figure 2.Global Nasal Drug Delivery Systems Market Share (%), by Region, 2022

Increasing product launches by market players is expected to drive the global nasal drug delivery systems market growth.

Increasing product launches by market players is expected to drive the market growth over the forecast period. For instance, on December 22, 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.), announced the launch of generic version of Narcan1 (naloxone hydrochloride nasal spray). Moreover, naloxone hydrochloride nasal spray is a prescription medicine used for the treatment of an opioid emergency such as an overdose or a possible opioid overdose with signs of breathing problems or inability to respond.

Global Nasal Drug Delivery Systems Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

The COVID-19 pandemic had a positive impact on the global nasal drug delivery systems market, owing to increased product launches by market players for protecting patients from coronavirus infection. For instance, on February 09, 2022, Glenmark Pharmaceuticals Limited, a global pharmaceutical company and Canada based pharmaceutical company SaNOtize Research & Development Corp., announced launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India for the treatment of adult patients with COVID-19 who have high risk of progression of the disease.

Global Nasal Drug Delivery Systems Market: Key Developments

On April 28, 2022, Birmingham Biotech, a company that offers a wide variety of in vitro diagnostic solutions, medical devices and equipment, announced the Singapore launch of its latest technology the BHM Anti-Viral Nasal Spray, an easy-to-use nasal device with a unique patented formulation, Norizite, designed to help prevent infection from the inhalation of airborne viruses within the nasal passages.

Global Nasal Drug Delivery Systems Market: Restraint

Limitations associated with nasal drug delivery system such as histological toxicity or lesser area of absorption as compared to orally administered drug hinders the nasal drug delivery systems market growth.

Key Players

Major players operating in the global nasal drug delivery systems market include Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Baxter International, Inc., Valeant Pharmaceuticals International, Inc., Becton, Dickinson and Company, and Novartis AG.

Table of Content

Table of Contents

*Browse 34 market data tables and 38 figures on "Global Nasal Drug Delivery Systems Market” - forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global nasal drug delivery systems market during the forecast period (2022-2030)?

The global nasal drug delivery systems market size is estimated to be valued at US$ 60.3 million in 2022 and is expected to exhibit a CAGR of 6.3% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increasing product approvals by regulatory authorities and increasing product launches by market players are major factors driving the market growth.

Which is the leading Dosage Form segment in the market?

Nasal Spray is the leading Dosage Form segment in the market.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include limitations associated with nasal drug delivery systems.

Which are the major players operating in the market?

Major players operating in the market include Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Baxter International, Inc., Valeant Pharmaceuticals International, Inc., Becton, Dickinson and Company, and Novartis AG.